Article
Cardiac & Cardiovascular Systems
Antonio L. Perez, Justin L. Grodin, Thanat Chaikijurajai, Yuping Wu, Adrian F. Hernandez, Javed Butler, Marco Metra, G. Michael Felker, Adriaan A. Voors, John J. Mcmurray, Paul W. Armstrong, Christopher O'Connor, Randall C. Starling, W. H. Wilson Tang
Summary: IL-6 levels may be associated with mortality and rehospitalization in acute heart failure patients, but the impact of nesiritide therapy on IL-6 levels remains inconclusive.
JOURNAL OF CARDIAC FAILURE
(2021)
Article
Cardiac & Cardiovascular Systems
P. Christian Schulze, Juergen Bogoviku, Julian Westphal, Pawel Aftanski, Franz Haertel, Sissy Grund, Stephan von Haehling, Ulrike Schumacher, Sven Moebius-Winkler, Martin Busch
Summary: This study suggests that early addition of empagliflozin to standard diuretic therapy can increase urine output in patients with acute decompensated heart failure without affecting renal function.
Article
Emergency Medicine
Kemal Gokcek, Aysel Gokcek, Birdal Yildirim, Ethem Acar, Omer Dogan Alatas, Ahmet Demir
Summary: In this study, the ACUTE HF score was found to be an independent predictor of in-hospital mortality in patients with AHF. Patients were categorized into low, intermediate, and high-risk groups based on the score, with a significant association between the score and mortality rate observed. More validation studies in different regions with diverse AHF populations are needed to determine the generalizability of the ACUTE HF score.
AMERICAN JOURNAL OF EMERGENCY MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Marianna Adamo, Matteo Pagnesi, Alexandre Mebazaa, Beth Davison, Christopher Edwards, Daniela Tomasoni, Mattia Arrigo, Marianela Barros, Jan Biegus, Jelena Celutkiene, Kamile Cerlinskaite-Bajore, Ovidiu Chioncel, Alain Cohen-Solal, Albertino Damasceno, Rafael Diaz, Gerasimos Filippatos, Etienne Gayat, Antoine Kimmoun, Carolyn S. P. Lam, Maria Novosadova, Peter S. Pang, Piotr Ponikowski, Hadiza Saidu, Karen Sliwa, Koji Takagi, Jozine M. Ter Maaten, Adriaan Voors, Gad Cotter, Marco Metra
Summary: The STRONG-HF study found that rapid up-titration of GRMT in a high intensity care strategy can improve outcomes in patients with acute HF. This study aimed to evaluate the role of NT-proBNP in early treatment. The results showed that regardless of baseline NT-proBNP levels, HIC was associated with a reduced risk of 180-day HF readmission or death compared to usual care.
EUROPEAN HEART JOURNAL
(2023)
Article
Pharmacology & Pharmacy
Tianyang Hu, Yiting Liu, Yake Lou
Summary: This study evaluated the cost-effectiveness of early or late initiation of Sacubitril-valsartan compared to enalapril in patients with acute decompensated heart failure (ADHF). The results showed that early initiation of Sacubitril-valsartan after stabilization from ADHF is highly cost-effective, while late initiation is still cost-effective but not as much as early initiation.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Zachary L. Cox, Hasan K. Siddiqi, Lynne W. Stevenson, Brian Bales, Jin H. Han, Kimberly Hart, Brant Imhoff, Juan B. Ivey-Miranda, Cathy A. Jenkins, Joann Lindenfeld, Matthew S. Shotwell, Karen F. Miller, Henry Ooi, Veena S. Rao, Kelly Schlendorf, Wesley H. Self, Edward D. Siew, Alan Storrow, Ryan Walsh, Jesse O. Wrenn, Jeffrey M. Testani, Sean P. Collins
Summary: Diuresis is a central aim in treating acute decompensated heart failure (ADHF). However, there is a lack of evidence on the optimal diuretic titration strategies. The ESCALATE trial aims to compare a urine chemistry-guided diuresis strategy with usual care in patients with ADHF. Primary outcome will assess the days of benefit in the 14 days following randomization.
AMERICAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Jasper Tromp, Piotr Ponikowski, Afshin Salsali, Christiane E. Angermann, Jan Biegus, Jon Blatchford, Sean P. Collins, Joao P. Ferreira, Claudia Grauer, Mikhail Kosiborod, Michael E. Nassif, Mitchell A. Psotka, Martina Brueckmann, John R. Teerlink, Adriaan A. Voors
Summary: The EMPULSE trial aims to assess the clinical benefits and safety of the SGLT2 inhibitor empagliflozin compared to placebo in patients hospitalized for AHF. Approximately 500 patients across North America, Europe, and Asia will be randomized to receive either empagliflozin or placebo, with the primary outcome being clinical benefit at 90 days. Secondary outcomes include safety assessments and changes in symptom scores and natriuretic peptides.
EUROPEAN JOURNAL OF HEART FAILURE
(2021)
Article
Cardiac & Cardiovascular Systems
Evelyne Meekers, Jeroen Dauw, Pieter Martens, Sebastiaan Dhont, Frederik H. Verbrugge, Petra Nijst, Jozine M. ter Maaten, Kevin Damman, Alexandre Mebazaa, Gerasimos Filippatos, Frank Ruschitzka, Wai Hong Wilson Tang, Matthias Dupont, Wilfried Mullens
Summary: The ADVOR trial demonstrated that acetazolamide has consistent diuretic effects across the entire range of renal function in patients with acute decompensated heart failure (ADHF). Acetazolamide increased the likelihood of successful decongestion, diuresis and natriuresis, especially in patients with lower estimated glomerular filtration rate (eGFR). Although acetazolamide was associated with a higher incidence of worsening renal function, it did not lead to adverse clinical outcomes.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Kanila Perera, Zanfina Ademi, Danny Liew, Ella Zomer
Summary: The study found that from the Australian healthcare perspective, the use of sacubitril-valsartan compared to enalapril in the management of acute decompensated heart failure may not be cost-effective. A price reduction of more than 25% is needed to confer cost-effectiveness.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Pieter Martens, Jeroen Dauw, Frederik H. Verbrugge, Petra Nijst, Evelyne Meekers, Silvio Nunes Augusto, Jozine M. Ter Maaten, Kevin Damman, Alexandre Mebazaa, Gerasimos Filippatos, Frank Ruschitzka, W. H. Wilson Tang, Matthias Dupont, Wilfried Mullens
Summary: Acetazolamide improved decongestion and diuretic response in patients with acute decompensated heart failure, regardless of their baseline left ventricular ejection fraction (LVEF).
Article
Cardiac & Cardiovascular Systems
Evan M. Murray, Stephen J. Greene, Vishal N. Rao, Jie-Lena Sun, Brooke A. Alhanti, Vanessa Blumer, Javed Butler, Tariq Ahmad, Robert J. Mentz
Summary: This study used machine learning and cluster analysis to classify and compare patients with HFpEF who are hospitalized for acute HF, and identified distinct phenotypes and clinical profiles among different clusters, as well as observed different outcomes.
AMERICAN HEART JOURNAL
(2022)
Article
Biochemistry & Molecular Biology
Evelyn M. Templeton, Moritz Lasse, Torsten Kleffmann, Leigh J. Ellmers, Suetonia C. Palmer, Trent Davidson, Nicola J. A. Scott, John W. Pickering, Christopher J. Charles, Zoltan H. Endre, Vicky A. Cameron, A. Mark Richards, Miriam T. Rademaker, Anna P. Pilbrow
Summary: One-quarter of patients with acute decompensated heart failure (ADHF) experience acute kidney injury (AKI), which is associated with increased long-term mortality. Currently, there is a critical need to identify early and real-time markers of AKI in ADHF; however, protein biomarkers with sufficient diagnostic or prognostic performance have not been widely adopted in clinical practice. This study aimed to identify novel protein biomarkers of AKI associated with ADHF by quantifying changes in protein abundance in the kidneys using a sheep model.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cardiac & Cardiovascular Systems
Teng-Yao Yang, Meng-shu Tsai, Jeng-Yu Jan, Jung-Jung Chang, Chang-Ming Chung, Ming-Shyan Lin, Hui-Ming Chen, Yu-Sheng Lin
Summary: Ivabradine is effective in controlling heart rate when initiated in patients with acute heart failure, but it does not seem to provide significant benefits in reducing heart failure hospitalization, all-cause hospitalization, and mortality after one year.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Joyce N. Njoroge, John R. Teerlink
Summary: ADHF is a leading admission diagnosis worldwide, with incompletely understood pathophysiology and limited therapeutic options. Patients often experience high in-hospital morbidity and mortality due to suboptimal medical management leading to persistent congestion upon hospital discharge and inadequate initiation of life-saving therapies before discharge. There has been no new therapy approved for ADHF in decades, highlighting the need for expanding available therapies for these high-risk patients.
CIRCULATION RESEARCH
(2021)
Review
Cardiac & Cardiovascular Systems
Tariq Ahmad, Yu Yamamoto, Aditya Biswas, Lama Ghazi, Melissa Martin, Michael Simonov, Allen Hsiao, Nitu Kashyap, Eric J. Velazquez, Nihar R. Desai, F. Perry Wilson
Summary: The REVeAL-HF trial aims to evaluate the impact of prognosis knowledge on clinical decision-making and patient outcomes. It is a pragmatic, completely electronic, randomized controlled trial that assesses the risk of 1-year mortality in adults hospitalized for HF. The trial will investigate the relationship between calculated, perceived, and real risk of mortality in this patient population.
JACC-HEART FAILURE
(2021)
Article
Endocrinology & Metabolism
Jelle M. Beernink, Frederik Persson, Niels Jongs, Gozewijn D. Laverman, Glenn M. Chertow, John J. V. McMurray, Anna Maria Langkilde, Ricardo Correa-Rotter, Peter Rossing, C. David Sjostrom, Robert D. Toto, David C. Wheeler, Hiddo J. L. Heerspink
Summary: This study aimed to determine whether the benefits of dapagliflozin varied by background glucose-lowering therapy (GLT) in patients with type 2 diabetes and chronic kidney disease (CKD). The results demonstrated consistent effects of dapagliflozin on both primary and secondary endpoints across different baseline GLT classes or combinations. Therefore, dapagliflozin has significant clinical implications in reducing kidney and cardiovascular events.
Letter
Endocrinology & Metabolism
Hertzel C. Gerstein, Emil Wolsk, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Sibylle Hess, Lars Kober, Aldo P. Maggioni, John J. V. McMurray, Jeffrey L. Probstfield, Matthew C. Riddle, Jean-Claude Tardif, Marc A. Pfeffer
DIABETES OBESITY & METABOLISM
(2023)
Article
Cardiac & Cardiovascular Systems
Ana Barat, Chien-Wei Chen, Natasha Patel-Murray, John J. V. McMurray, Milton Packer, Scott D. Solomon, Akshay S. Desai, Jean L. Rouleau, Michael R. Zile, Zenab Attari, Cong Zhang, Huilei Xu, Nicole Hartman, Claudia Hon, Margaret Healey, William Chutkow, Christopher J. O'Donnell, Jaison Jacob, Marty Lefkowitz, Michael M. Mendelson, Simon Wandel, Denise Yates, Claudio Gimpelewicz
Summary: This study aimed to evaluate the prevalence of pathogenic variants in genes associated with DCM in a population with heart failure and reduced ejection fraction (HFrEF) and describe the baseline characteristics by variant carrier status. The study analyzed data from the PARADIGM-HF trial and found that around 5% of HFrEF patients had deleterious pLoF variants in genes strongly associated with DCM. These carriers were younger, had lower ejection fraction, and were less likely to have an ischaemic etiology compared to non-carriers.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Safia Chatur, Jonathan W. Cunningham, Muthiah Vaduganathan, Finnian R. Mc Causland, Brian L. Claggett, Akshay S. Desai, Zi Michael Miao, Pardeep S. Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Carolyn S. P. Lam, Felipe A. Martinez, Sanjiv J. Shah, Magnus Petersson, Anna Maria Langkilde, John J. V. McMurray, Scott D. Solomon
Summary: In patients recently hospitalized for heart failure, dapagliflozin can reduce the risk of hospitalization and has minimal effects on blood pressure and renal function. It is a safe and effective treatment option for stabilized patients with heart failure.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Kirsty McDowell, Ross Campbell, Joanne Simpson, Jonathan W. Cunningham, Akshay S. Desai, Pardeep S. Jhund, Martin P. Lefkowitz, Jean L. Rouleau, Karl Swedberg, Michael R. Zile, Scott D. Solomon, Milton Packer, John J. V. McMurray
Summary: This study investigated the improvement in risk prediction of heart failure by adding candidate biomarkers to comprehensive models with routinely collected clinical and laboratory variables. Four biomarkers (hs-TnT, GDF-15, cystatin C, and TIMP-1) were independently associated with all outcomes. However, only hs-TnT remained an independent predictor of the three endpoints when all biomarkers were added simultaneously to the PREDICT-HF model. Individually or in combination, the other biomarkers did not significantly improve discrimination or reclassification of prediction.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Editorial Material
Medicine, General & Internal
John J. V. McMurray, Marco Metra
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Alexander Peikert, Alvin Chandra, Mikhail N. Kosiborod, Brian L. Claggett, Akshay S. Desai, Pardeep S. Jhund, Carolyn S. P. Lam, Silvio E. Inzucchi, Felipe A. Martinez, Rudolf A. de Boer, Adrian F. Hernandez, Sanjiv J. Shah, Stefan P. Janssens, Jan Belohlavek, C. Jan Willem Borleffs, Dan Dobreanu, Anna Maria Langkilde, Olof Bengtsson, Magnus Petersson, John J. V. McMurray, Scott D. Solomon, Muthiah Vaduganathan
Summary: In this study, dapagliflozin was found to improve the overall health status of heart failure patients. The improvements were particularly significant in domains related to symptom frequency and physical limitations, which are more easily recognized and communicated to patients.
Article
Cardiac & Cardiovascular Systems
Pardeep S. Jhund, Brian L. Claggett, Atefeh Talebi, Jawad H. Butt, Samvel B. Gasparyan, Lee-Jen Wei, Zachary R. McCaw, Ulrica Wilderaeng, Olof Bengtsson, Akshay S. Desai, Magnus Petersson, Anna Maria Langkilde, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Carolyn S. P. Lam, Felipe A. Martinez, Sanjiv J. Shah, Muthiah Vaduganathan, Scott D. Solomon, John J. V. McMurray
Summary: In the DELIVER trial, dapagliflozin reduced the risk of first worsening heart failure event or cardiovascular death in patients with heart failure. This study aimed to evaluate the effect of dapagliflozin on total heart failure events and cardiovascular death. The results showed that dapagliflozin reduced the rate of total heart failure events and cardiovascular death regardless of left ventricular ejection fraction (EF).
Article
Cardiac & Cardiovascular Systems
Pascal. M. Burger, Gianluigi Savarese, Jasper Tromp, Carly Adamson, Pardeep. S. Jhund, Lina Benson, Camilla Hage, Wan Ting Tay, Scott. D. Solomon, Milton Packer, Xavier Rossello, John. W. McEvoy, Dirk De Bacquer, Adam Timmis, Panos Vardos, Lan. M. Graham, Emanuele Di Angelantonio, Frank L. J. Visseren, John. J. McMurray, Carolyn S. P. Lam, Lars. H. Lund, Stefan Koudstaal, Jannick A. N. Dorresteijn, Arend Mosterd
Summary: The LIFE-HF model is a tool for estimating lifelong survival and treatment benefit in HFrEF patients, which can improve the management of HFrEF and facilitate personalized medicine and shared decision-making.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Shingo Matsumoto, Toru Kondo, Mingming Yang, Ross T. Campbell, Kieran F. Docherty, Rudolf A. de Boer, Akshay S. Desai, Carolyn S. P. Lam, Milton Packer, Bertram Pitt, Jean L. Rouleau, Muthiah Vaduganathan, Faiez Zannad, Michael R. Zile, Scott D. Solomon, Pardeep S. Jhund, John J. V. McMurray
Summary: This study investigated the association between the use of calcium channel blockers (CCBs) and clinical outcomes in patients with heart failure (HF) and found that CCB use was not significantly associated with worse outcomes in HF patients.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Kieran F. Docherty, Alice M. Jackson, Mark Macartney, Ross T. Campbell, Mark C. Petrie, Marc A. Pfeffer, John J. V. McMurray, Pardeep S. Jhund
Summary: The risk of heart failure hospitalization (HFH) following acute myocardial infarction (AMI) has decreased in Scotland over the past 25 years, likely due to improvements in coronary reperfusion and secondary prevention therapies.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
Akshay S. Desai, Anita Deswal, John J. V. McMurray, Sean P. Pinney, Muthiah Vaduganathan
JACC-HEART FAILURE
(2023)
Article
Urology & Nephrology
Sunil Bhandari, Patrick Parfrey, Claire D. White, Stefan Anker, Kenneth Farrington, Ian A. Ford, Philip Kalra, John J. V. McMurray, Michele Robertson, Charles R. V. C. Tomson, David C. Wheeler, Iain Macdougall
Summary: This study analyzed the baseline quality of life measures in participants from the PIVOTAL trial and found that quality of life was impaired in patients starting hemodialysis. A higher C-reactive protein level was consistently associated with worse quality of life. Transferrin saturation was also found to be a predictor of worse physical component score of quality of life.
JOURNAL OF NEPHROLOGY
(2023)
Correction
Cardiac & Cardiovascular Systems
James P. Curtain, Carly Adamson, Toru Kondo, Jawad Haider Butt, Akshay S. Desai, Faiez Zannad, Jean L. Rouleau, Luis E. Rohde, Lars Kober, Inder S. Anand, Dirk J. van Veldhuisen, Michael R. Zile, Martin P. Lefkowitz, Scott DSolomon, Milton Packer, Mark C. Petrie, Pardeep S. Jhund, John J. V. McMurray
EUROPEAN HEART JOURNAL
(2023)
Letter
Medicine, General & Internal
Scott D. Solomon, Muthiah Vaduganathan, John J. V. McMurray
NEW ENGLAND JOURNAL OF MEDICINE
(2023)